The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ImmunoMet Therapeutics‘ treatment…
Articles by Marisa Wexler, MS
Severely reduced lung function is not closely related to walking ability in people with idiopathic pulmonary fibrosis (IPF), a…
The Pulmonary Fibrosis Foundation (PFF)Â announced that United Therapeutics will sponsor the PFF Registry. The Registry is a…
A four-year, $2.4 million federal grant given investigators at Boston University School of Medicine (BUSM) will support work to create a…
The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, announced the winners of a…
People with prediabetes or diabetes who live in smog-filled cities may be more prone to pulmonary fibrosis as a result…
The U.S. Food and Drug Administration (FDA) has granted treprostinil orphan drug designation for the treatment of idiopathic pulmonary…
The global COVID-19 pandemic has had a negative local impact on healthcare for most people in the U.K. with…
Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies,…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization…